With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.20759-14-2,Ruthenium(III) chloride hydrate,as a common compound, the synthetic route is as follows.
(4) Preparation of trans-3′-oxospiro[cyclohexane-1,1′(3’H)-isobenzofuran]-4-carboxylic acid A mixture of 4-hydroxymethylspiro[cyclohexane-1,1′(3’H)-isobenzofuran]-3′-one (190 mg), chloroform (2.0 mL), acetonitrile (2.0 mL) and sodium phosphate buffer (pH6.5, 2.0 mL) was cooled to 0 C., to which sodium periodate (612 mg) and ruthenium(III) chloride n-hydrate (10 mg) were added and the mixture was stirred for 30 minutes. The reaction mixture was stirred together with 1N hydrochloric acid (2.0 mL) for 30 minutes and partitioned between water (50 mL) and ethyl acetate (50 mL). The organic layer was washed with saturated saline solution, dried over anhydrous Na2SO4 and then concentrated. The residue was purified by column chromatography on silica gel (chloroform/methanol=100/1) to give the subject compound (98.6 mg).
As the paragraph descriping shows that 20759-14-2 is playing an increasingly important role.
Reference£º
Patent; Banyu Pharmaceutical Co., Ltd.; US6326375; (2001); B1;,
Highly efficient and robust molecular ruthenium catalysts for water oxidation
Catalysts | Special Issue : Ruthenium Catalysts – MDPI